Sierra Oncology

News

GSK gets June 2023 FDA decision date for momelotinib

The clock is now ticking on the FDA's review of GSK's momelotinib for myelofibrosis patients with anaemia – the centrepiece of its $1.9 billion

News

GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy

GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US biotech's shares skywards.<

News

NHS staff 'feel unprepared for digital transformation'

A survey of NHS workers has found that almost two-thirds feel they are unprepared for the digital transformation objectives of the 10-Year Plan.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks